| Company Name | Akums Drugs and Pharmaceuticals Limited |
| Open Date | 30-07-2024 |
| Close Date | 01-08-2024 |
| Exchange | BSE, NSE |
| Lot Size | 22 Shares |
| Issue Price | ₹646 to ₹679 per share |
| Issue Size | 2,73,45,162 shares |
| Application Amount | ₹ 14,938 – ₹ 1,94,194 (22 to 286 shares) |
| Recommendation | Avoid |
Akum Drugs and Pharmaceuticals Limited was established on April 19, 2004. The registered office is located at Saraswati Vihar, Delhi. The Company is offering Contract Development and Manufacturing Organization (CDMO), Research &
Development (R&D) and Active Pharmaceutical ingredients (API) services. As of March 31, 2024, the key clients of the company include Alembic Pharmaceuticals, Alkem Laboratories, Blue Cross Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories etc. The company had 7,388 permanent employees and 8,739 on contractual basis as of March 31, 2024.
| KPI’s | FY 22 | FY 23 | FY 24 |
| Revenue | 3,671.89 | 3,654.82 | 4,178.18 |
| EBITDA | -91.52 | 337.75 | 122.98 |
| Net Profit | -250.87 | 97.82 | 0.79 |
| RoCE | -10.36% | 11.24% | -0.12% |
| ROE | -40.13% | 13.52% | 0.11% |
| P/E | -38.47 | 102.41 | -2,425.00 |
| Opening Date | 30/07/2024 |
| Closing Date | 01-08-2024 |
| Basis of Allotment | 02-08-2024 |
| Initiation of Refunds | 05-08-2024 |
| Credit of Shares to Demat | 05-08-2024 |
| Listing Date | 06-08-2024 |
| Repayment/ prepayment of indebtedness of the company and its subsidiaries. |
| Funding incremental working capital requirements of the company. |
| Pursuing inorganic growth initiatives through acquisitions. |
| General Corporate Expenses. |
| Registered Office | Akums Drugs and Pharmaceuticals Limited 304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034 |
| Phone | +91 11 6904 1000 |
| cs@akums.net | |
| Website | http://www.akums.in/ |
| Name | Link Intime India Private Ltd |
| Phone | +91-22-4918 6270 |
| akumsdrugs.ipo@linkintime.co.in | |
| Website | https://linkintime.co.in/initial_offer/public-issues.html |
| QIB Shares Offered | Not less than 75.00% of the Net offer |
| Retail Shares Offered | Not more than 10.00% of the Offer |
| NII (HNI) Shares Offered | Not less than 15.00% of the Offer |
| Share Holding Pre Issue (Promoters) | 82.44% |
| Share Holding Post Issue (Promoters) | 66.18% |